Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
Carcinoma, Hepatocellular
PROCEDURE: Cryoablation|DRUG: PD-1 antibody and bevacizumab
Progression-free survival, mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit., Up to 2 years
Time to progress, mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit., Up to 2 years|Objective Response Rate, mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit., Up to 2 years|Overall survival, According to medical documents or descriptions of the patient's family, Up to 2 years|Adverse events, CTCAE v5.0 is used to assess adverse events., Up to 2 years
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.